13F Pro

SEC Form 4 reporting owner

Baker Bros. Advisors LP

Baker Bros. Advisors LP has filed 40 Form 4 transactions reported between December 11, 2025 and September 14, 2026, as a reporting owner of BeOne Medicines Ltd., a reporting owner of Replimune Group, Inc., a reporting owner of Celcuity Inc., a reporting owner of Kodiak Sciences Inc., a reporting owner of INCYTE CORP, a reporting owner of vTv Therapeutics Inc., a reporting owner of Kymera Therapeutics, Inc., a reporting owner of MADRIGAL PHARMACEUTICALS, INC., a reporting owner of Prelude Therapeutics Inc, a reporting owner of Denali Therapeutics Inc., a reporting owner of ACADIA PHARMACEUTICALS INC, a reporting owner of Kiniksa Pharmaceuticals International, plc, a reporting owner of TScan Therapeutics, Inc., a reporting owner of DBV Technologies S.A. and a reporting owner of BICYCLE THERAPEUTICS PLC.

Name as filed: BAKER BROS. ADVISORS LP

Open-market buys, 24 mo
$315.5M
10 lines
Open-market sales, 24 mo
$317.8M
2 lines
Companies
15
with Form 4 filings
Latest transaction
Sep 14, 2026
transaction date

Roles and reported holdings

  • ONCBeOne Medicines Ltd.
    May 22, 2026 – Sep 14, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

    2 lines are priced far from ONC’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

  • REPLReplimune Group, Inc.
    Apr 1, 2026 – Aug 11, 2026

    Reporting owner

    Held indirectly (latest line)2,609,946 sh as of Aug 11, 2026 · Form 4

    24 months: $33.0M bought

  • CELCCelcuity Inc.
    Jul 14, 2026

    Reporting owner

    Held indirectly (latest line)4,372,852 sh as of Jul 14, 2026 · Form 4

    24 months: $317.8M sold

  • KODKodiak Sciences Inc.
    Dec 18, 2025 – Jun 30, 2026

    Reporting owner

    Held indirectly (latest line)18,358,772 sh as of Dec 18, 2025 · Form 4

    24 months: $60.0M bought

  • INCYINCYTE CORP
    Dec 31, 2025 – Jun 30, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • VTVTvTv Therapeutics Inc.
    Jun 26, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • KYMRKymera Therapeutics, Inc.
    Dec 11, 2025 – Jun 24, 2026

    Reporting owner

    Held indirectly (latest line)7,955,916 sh as of Dec 11, 2025 · Form 4

    24 months: $172.5M bought

  • MDGLMADRIGAL PHARMACEUTICALS, INC.
    Jun 17, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • PRLDPrelude Therapeutics Inc
    Apr 21, 2026 – Jun 9, 2026

    Reporting owner

    Held indirectly (latest line)20,105,994 sh as of Apr 21, 2026 · Form 4

    24 months: $10.0M bought

  • DNLIDenali Therapeutics Inc.
    Dec 11, 2025 – Jun 3, 2026

    Reporting owner

    Held indirectly (latest line)25,996,310 sh as of Dec 11, 2025 · Form 4

    24 months: $40.0M bought

  • ACADACADIA PHARMACEUTICALS INC
    May 29, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • KNSAKiniksa Pharmaceuticals International, plc
    May 29, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • TCRXTScan Therapeutics, Inc.
    May 20, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • DBVTDBV Technologies S.A.
    Jan 12, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • BCYCBICYCLE THERAPEUTICS PLC
    Jan 2, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 40 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 14, 2026ONCOption exerciseCode M · indirect30,768$1.1M@ $36.83Form 4
Aug 11, 2026REPLOpen-market purchaseCode P · indirect2,609,946$31.5M@ $12.06Form 4
Aug 11, 2026REPLOpen-market purchaseCode P · indirect126,394$1.5M@ $12.06Form 4
Jul 14, 2026CELCOpen-market saleCode S · indirect2,838,632$291.0M@ $102.50Form 4
Jul 14, 2026CELCOpen-market saleCode S · indirect261,368$26.8M@ $102.50Form 4
Jun 30, 2026KODGrant or awardCode A · indirect17,731—Form 4
Jun 30, 2026INCYGrant or awardCode A · indirect400—Form 4
Jun 26, 2026VTVTGrant or awardCode A · indirect6,000—Form 4
Jun 24, 2026KYMRGrant or awardCode A · indirect6,068—Form 4
Jun 17, 2026MDGLGrant or awardCode A · indirect1,532—Form 4
Jun 17, 2026MDGLGrant or awardCode A · indirect908—Form 4
Jun 11, 2026ONCGrant or awardCode A · indirect18,980—Form 4
Jun 9, 2026PRLDGrant or awardCode A · indirect38,000—Form 4
Jun 8, 2026INCYGrant or awardCode A · indirect6,111—Form 4
Jun 8, 2026INCYGrant or awardCode A · indirect1,642—Form 4
Jun 3, 2026DNLIGrant or awardCode A · indirect19,226—Form 4
Jun 3, 2026DNLIGrant or awardCode A · indirect6,408—Form 4
May 29, 2026ACADGrant or awardCode A · indirect32,008—Form 4
May 29, 2026ACADGrant or awardCode A · indirect18,622—Form 4
May 29, 2026KNSAGrant or awardCode A · indirect36,474—Form 4
May 29, 2026KNSAGrant or awardCode A · indirect6,078—Form 4
May 22, 2026ONCOpen-market saleCode S · indirectPrice far from market; may be another security2,756$66K@ $23.79Form 4
May 22, 2026ONCOpen-market saleCode S · indirectPrice far from market; may be another security2,743$65K@ $23.85Form 4
May 20, 2026TCRXGrant or awardCode A · indirect67,000—Form 4
May 8, 2026INCYOption exerciseCode M · indirect15,000$1.3M@ $84.53Form 4
Apr 21, 2026PRLDOpen-market purchaseCode P · indirect2,137,651$9.5M@ $4.44Form 4
Apr 21, 2026PRLDOpen-market purchaseCode P · indirect114,601$509K@ $4.44Form 4
Apr 1, 2026REPLGrant or awardCode A · indirect44,500—Form 4
Mar 31, 2026INCYGrant or awardCode A · indirect421—Form 4
Jan 12, 2026DBVTOption exerciseCode M · indirect25,005,240—Form 4
Jan 12, 2026DBVTOption exerciseCode M · indirect2,299,656—Form 4
Jan 2, 2026BCYCGrant or awardCode A · indirect38,000—Form 4
Jan 2, 2026BCYCGrant or awardCode A · indirect19,000—Form 4
Dec 31, 2025INCYGrant or awardCode A · indirect328—Form 4
Dec 18, 2025KODOpen-market purchaseCode P · indirect2,391,268$55.0M@ $23.00Form 4
Dec 18, 2025KODOpen-market purchaseCode P · indirect217,428$5.0M@ $23.00Form 4
Dec 11, 2025KYMROpen-market purchaseCode P · indirect1,838,621$158.1M@ $86.00Form 4
Dec 11, 2025KYMROpen-market purchaseCode P · indirect167,192$14.4M@ $86.00Form 4
Dec 11, 2025DNLIOpen-market purchaseCode P · indirect2,095,191$36.6M@ $17.49Form 4
Dec 11, 2025DNLIOpen-market purchaseCode P · indirect190,523$3.3M@ $17.49Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

2 open-market lines are priced outside 0.67×–1.5× of the stock’s closing price that day. A gap that large usually means the filing reports a different security than the company it is filed under, so those lines are shown but left out of totals and holdings.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.